Ghrelin is a metabolic hormone that has neuroprotective actions in a number of neurological conditions, including Parkinson's disease (PD), stroke and traumatic brain injury. Acyl ghrelin treatment in vivo and in vitro also shows protective capacity in Alzheimer's disease (AD). In the present study, we used ghrelin knockout (KO) and their wild-type littermates to test whether or not endogenous ghrelin is protective in a mouse model of AD, in which human amyloid β peptide 1-40 (Aβ 1-40 ) was injected into the lateral ventricles i.c.v. Recognition memory, using the novel object recognition task, was significantly impaired in ghrelin KO mice and after i.c.v. Aβ 1-40 treatment.
secretagogue receptor; GHSR), which is located in several regions throughout the brain, including the hypothalamus, substantia nigra, olfactory bulb, brain stem and hippocampus. 3 In terms of neuroprotection, numerous studies have reported that ghrelin prevents degeneration in animal models of Parkinson's disease (PD) . Recently, we demonstrated that ghrelin mediates the neuroprotective benefit of energy restriction in PD by controlling AMPK in substantia nigra dopamine neurones. 4 Of course, energy restriction will impact upon numerous physiological systems and recent evidence shows that ghrelin may link energy restriction with increased neurogenesis, 5 blood glucose production 6, 7 and mood. 8 Collectively, these studies show that ghrelin is a signal of energy deficit to the brain and that the effective actions of ghrelin are greater in states of negative energy balance. 2, 9 Alzheimer's disease (AD) is another neurological disease that may benefit from forms of energy restriction. 10, 11 If ghrelin was a common neuroendocrine feedback signal linking metabolic state to neuroprotection, then it is expected that ghrelin would also promote neuronal resilience in different models of AD. Indeed, human males with mild stage AD show significantly lower plasma ghrelin than aged-matched controls, although no difference in females was observed. 12 A single nucleotide polymorphism (Leu90Gln) in the ghrelin gene was associated with age of AD onset in a Japanese population. 13 Moreover, a number of in vivo and in vitro studies show that ghrelin or GHSR agonists improve cognition and neuronal function in models of AD.
For example, peripheral ghrelin improved T-maze footshock avoidance in a U-shaped dose-response curve in young and old SAMP8 KO mice, 14 which exhibit an age-related increase in amyloid β (Aβ), the peptide involved in brain amyloid plaques in AD and impaired learning and memory. 14 Moon et al. 15 reported that peripheral ghrelin injections rescue memory deficits, prevent microgliosis and neuronal or synaptic degeneration in an AD mouse model induced by intrahippocampal injections of Aβ. These results have been confirmed with a central infusion of acyl ghrelin, which improved memory function, hippocampal AMPK activation and decreased Aβ deposition. 16 In cultured hippocampal neurones, ghrelin ameliorated Aβ-induced cell death by preventing mitochondrial dysfunction.
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In the 5XFAD AD mouse model, hippocampal neuroblast number is significantly reduced compared to wild-type (WT) controls and peripheral ghrelin injections restore this neurogenic capacity; whether or not this produced any functional recovery was not examined. 18 However, these results are consistent with acyl-ghrelin-induced adult hippocampal neurogenesis via hippocampal GHSR activation in healthy lean mice 5 and rats. 19 Long-term treatment with the GHSR agonist, LY444711, improves performance in a water maze and reduces microglial activation and Aβ. 20 However, recent work from the same group using the same agonist failed to replicate this finding.
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Although the studies outlined above demonstrate that administration of ghrelin improves outcomes in mouse or rat models of AD, or in vitro, there is no evidence to support the idea that endogenous ghrelin provides a protective effect preventing or restricting cognitive loss in models of AD. Therefore, in the present study, we have used ghrelin
WT and ghrelin knockout (KO) mice to determine whether or not endogenous ghrelin prevents cognitive decline after i.c.v. Aβ administration. We further examined the protective actions of acyl ghrelin administration in ghrelin WT and KO mice and explored the possible impact of ghrelin and Aβ in two processes known to critically impact on memory performance: neuroinflammation and synaptic plasticity.
| MATERIALS AND METHODS

| Animals
All experiments were conducted in compliance with the guidelines of 
| Treatment
Ghrelin KO mice that produce neither acylated, nor des-acylated ghrelin 22, 23 were used to examine whether endogenous ghrelin prevents cognitive decline and neuroinflammation after i. 
| Behavioural testing
Behaviour testing occurred between days 6 and 17 after the start of the ghrelin injections and mice were tested for novel objection recognition, Y-maze performance and olfactory discrimination in accordance with the timeline established in Figure 1 . All behavioural tests were conducted at least 2 days apart to reduce any potential stress associated with behavioural testing. All behavioural testing was conducted between 09.00 hours and 14.00 hours.
All tests were performed in an experimental room with sound isolation and dim light. The animals were carried to the test room for at least 1 hour of acclimation. Behaviour was monitored using a video camera positioned above the apparatus and the videos were analysed subsequently by an experienced blinded researcher using video tracking software (CleverSys Inc., Reston, VA, USA).
| Novel object recognition (NOR)
The NOR task exploits a mouse's natural tendency to explore a novel object after previous exposure to two identical objects. At 10-12 weeks of age, mice (n=8) were habituated for three periods of 10 minutes each separated with 10 minutes in its home cage to reduce anxiety associated with the novel arena (plastic arena 30×30×50 cm). After habituation, mice were ready for the NOR task, which was conducted using two trials (familarisation trial [T1] and test trial [T2]) separated by 30 minutes. During T1, for 10 minutes, mice were allowed to explore two identical objects (plastic screw-top tubes) secured to the floor using a small amount of re-usable adhesive in habituated arenas. For T2, one identical object from T1 was replaced with a novel object (small green flask) and mice were allowed to freely explore for 5 minutes. T1 and T2 were recorded using a video camera and analysed with respect to the time spent interacting with the novel object. All arenas were washed and dried and then sprayed with 80% ethanol prior to experimentation. Novel object exploration was calculated in T2 by (T novel ×100)/(T novel +T identical ), with exploration defined as the nose being less than 1 cm from the object when facing the object or actively engaging with the object by sniffing or paw touching. Climbing on the object was not considered as exploration.
| Modified Y-maze
The modified Y-maze measures spatial memory because spatial orientation cues facilitate rodents to explore a novel arm rather than returning to a previously visited arm. We used a Y-shaped grey Perspex maze (30×10×16 cm) and each arm could be isolated by blocking entry with a sliding door. Saw dust from a mouse's home cage lined the maze during the trials and extra maze cues on the walls were placed 30-40 cm from the end of the arms to provide spatial orientation cues. Behaviour was tested across two trials, the first of which had one arm of the maze randomly blocked off. Mice were allowed to explore the reduced maze for 10 minutes and then returned to their home cage. The second trial was conducted 30 minutes after the first trial and both arms of the maze were opened. Mice were placed in the start arm and allowed to explore the full maze for 5 minutes.
All behaviours were recorded and analysed using tracking software.
Novel arm exploration was record when all four feet of each mouse entered the novel arm. The apparatus was cleaned with 80% ethanol between each trial and each animal.
| Olfactory discrimination
The task is based on the fact that mice prefer places with their own The time spent in each chamber was recorded and analysed. An olfactory discrimination index was generated according to: t familiar /(t familiar + t nonfamiliar ), where t equals time and 0.5 equals no preference.
| Immunohistochemistry and stereology
We collected every section (30 μm thickness) in sets of four through the rostral hippocampus from bregma −0.9 mm to -2. 
| Stereology
We employed a design-based approach to quantify GFAP-and
Iba1-positive cells in the rostral hippocampus using STereOiNveSTigATOr (MicroBrightField, Williston, VT, USA). We used a microscope with a motorised stage (Carl Zeiss, Oberkochen, Germany). Cells were counted using the optical fractionator probe on both sides of 
| Electrophysiology
Electrophysiological recordings were carried out as described previously. 27 Briefly, mice (C57Bl/6) were deeply anaesthetised under a halothane-saturated atmosphere (Sigma-Aldrich) before decapitation.
Brains were quickly removed and placed in ice-cold standard artifi- Averages of four consecutive responses were continuously monitored on a personal computer with lTp, version 1.0.1. ), both were added simultaneously to the superfusion system 30 minutes before LTP induction.
| Statistical analysis
All data are represented as the mean±SEM. A three-way ANOVA, or a two-way ANOVA, with Tukey's post hoc tests for multiple comparsions were used to determine statistical significance between genotype, peptide and hormone treatment. P<.05 was considered statistically significant. Data were plotted and analysed using Prism, version 7.0b (GraphPad Software Inc., San Diego, CA, USA).
| RESULTS
| NOR
The NOR is a highly-validated test for recognition memory and exploits the natural tendency of a mouse to explore a novel object after previous exposure to two identical objects. To examine the effect of i.c.v. 
| Modified Y-maze
The modified Y-maze is a highly-validated test for spatial memory, which utilises spatially orientated visual cues to help rodents explore a previously unexplored novel arm. To examine the effect of i.c. Figure 3C ). Thus, deletion of ghrelin or Aβ alone reduces novel arm exploration to a similar degree, which cannot be reduced further in ghrelin KO mice after Aβ 1-40 .
| Olfactory discrimination
Because deficits in olfactory processing are a common feature in early stages of AD 29 and ghrelin regulates olfactory processing in mice and humans, 30 we used an olfactory discrimination test to determine whether Aβ 1-40 affects olfactory discrimination in ghrelin WT and KO mice. We also tested whether exogenous acyl ghrelin could improve olfactory discrimination in ghrelin WT and KO mice.
Specifically, we chose to examine olfactory behaviour 10 days after the final acyl ghrelin i.p. injection because olfactory discrimination is reported to require olfactory neurogenesis [31] [32] [33] [34] and this time frame influences hippocampal neurogenesis. 35 A three-way ANOVA revealed a main effect of genotype (F=30.91; P<.0001) and no effects of hormone treatment or peptide treatment were observed.
Moreover, no significant interactions were observed. All WT groups of mice could discriminate between chambers paired with familiar and fresh bedding (ie, discrimination index >0.5) (Figure 4 ). 
| Stereological analysis of GFAP and Iba1 in the rostral hippocampus
To examine the effect of 
| Hippocampal LTP
The electrophysiological analysis in hippocampal slices revealed that Figure 6C,D) .
F I G U R E 4
Olfactory discrimination was determined by comparing the amount of time mice spent in a chamber with familiar bedding compared to the time spent in an adjoining chamber with nonfamiliar bedding. The olfactory discrimination index measures the preference for the familiar bedding, with 0.5 being equal to no preference, as indicated by the dotted line. We observed a main effect of genotype on olfactory discrimination, but no effect of hormone or peptide treatment, indicating that ghrelin knockout (KO) mice performed worse than wild-type (WT) mice, independent of acyl ghrelin or Aβ 1-40 treatment. Data are presented as the mean±SEM (n=10 per group), three-way ANOVA with Tukey's post hoc analysis to identify any significant difference between groups 
| DISCUSSION
The results of the present study highlight five key findings: (i) ghrelin The particular ability of ghrelin deletion to dampen memory performance and, conversely, that of exogenous acyl ghrelin to restore memory selectively when is it perturbed, strongly suggests a critical role of ghrelin in preventing memory deterioration rather than acting as a memory enhancer. This is supported by the observations that acyl ghrelin did not enhance memory performance in ghrelin WT mice without Aβ administration.
Furthermore, based on the proposed detrimental role of soluble Aβ in early AD, 36,37 the reported findings consolidate the therapeutic potential of manipulating ghrelin signalling in the brain to manage early AD. [15] [16] [17] 38 This is further indicated by the ability of ghrelin to control two key processes that we have previously shown to critically mediate the early memory dysfunction as a result of the i.c.v. administration of Aβ, namely neuroinflammation 39 and synaptic dysfunction. 40, 41 It still remains to be determined whether ghrelin might also affect classical pathological features of late phases of AD such as the formation of amyloid plaques and the aggregation of phosphorylated tau because these two features are not recapitulated in the Aβ1-40 i.c.v. injection model, 36, 37 which mostly mimics early AD, as validated in numerous studies. 24, 36, 39, 42, 43 The spatial Y maze memory test is highly validated and depends on hippocampal function, whereas recognition memory is largely perirhinal-dependent but with a hippocampal component. [44] [45] [46] Our studies and the work performed by Diano et al.
14 support a role for ghrelin in the hippocampus in object recognition; however, the role of ghrelin in the perirhinal cortex, a key site for object recognition, 47 needs to be addressed. We show for the first time that spatial memory is also dependent on endogenous ghrelin production because ghrelin KO mice showed deficits in Y-maze (spatial memory) performance that in the hippocampus to promote spatial memory performance. 48, 49 It should be noted, however, that GHSR deficient rats showed a deficit in a radial arm maze food motivated task but not in the water maze,
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suggesting that ghrelin may control context-dependent spatial memory via GHSR signalling, 5 for which there is high expression in the hippocampus, particularly the rostral dentate gyrus. 3, 19, 51 Considering the important role of ghrelin and GHSR signalling in conveying energy deficit, it is likely that ghrelin/GHSR signalling in the hippocampus enhances spatial learning to promote re-feeding and restoration of energy balance. 52, 53 However, this ghrelin/GHSR signalling may operate differently in different brain regions because contextual fear memory is also dependent on GHSR 5 but is independent of energy balance. by an unbiased stereological approach, one of the most reliable and robust methods for accurately estimating cell number within a large area. 55 These results are consistent with the known roles of ghrelin in preventing neuroinflammation in models of AD and other neurological disorders 26, 56 and the ability of Aβ to induce neuroinflammation. 57 The control of synaptic plasticity, which is the best neurophysiological correlate of memory, 58 is another mechanism likely involved in the effects of Aβ 1-40 and ghrelin on hippocampal-dependent memory. Indeed, the onset of memory impairment in early AD appears to depend on synaptic dysfunction 59 and we now report that the known deleterious effect of Aβ 1-40 on hippocampal LTP 60 is prevented by the addition of ghrelin.
This provides a neurophysiological basis for the ability of ghrelin to prevent Aβ 1-40 -induced dysfunction.
We also showed that deletion of ghrelin significantly impairs olfactory discrimination, which has significant implication in AD because deficits in olfactory processing are a common feature in early stage AD. 29 To the best of our knowledge, this is the first study to demonstre that endogenous ghrelin modulates olfactory function. Our results are consistent with ghrelin influencing olfactory responsiveness to odours, which can be blocked by ghrelin receptor antagonism, 61 as well as ghrelin increasing sniffing frequency in mice and humans. 30 Together with the high expression of the GHSR in the olfactory bulb, Given the expression of the GHSR in the olfactory bulb and the strong effects of ghrelin in the olfactory responsiveness and sniffing frequency, the lack of olfactory learning in response to i.p. acyl ghrelin treatment was initially surprising. This is likely a result of the different mechanisms of action of ghrelin/GHSR signalling with respect to controlling different memory domains encoded by different brain circuits.
By contrast to the control of hippocampal-dependent spatial memory, which may involve neuroinflammation and synaptic plasticity based on our data, the ghrelin/GHSR-mediated control of the consolidation of contextual fear memory instead requires the down-regulation of GHSR in the amygdala. 54 The effect of endogenous ghrelin on olfactory memory might involve a different mechanism, such as ghrelin-induced neurogenesis, 5, 62 which is known to affect olfactory discrimination. 31, 32 This would explain the observed lack of effect of i.p. acyl ghrelin because the generation of functioning new adult born olfactory bulb neurones takes approximately 28 days 62 and acyl ghrelin would be ineffective following 11 days of treatment, 63 when we analysed olfactory memory. 5, [31] [32] [33] [34] 62 Future studies are required to address the relationship between ghrelin-induced olfactory bulb neurogenesis and olfactory learning.
In the present study, we have tested the cognitive effects of Aβ i.c.v. treatment in ghrelin WT and KO mice with or without acyl ghrelin treatment. Importantly, ghrelin KO mice lack both des-acyl ghrelin and acyl ghrelin because both forms are derived from the same proghrelin precursor. Thus, it is possible that the lack of des-acyl ghrelin may also contribute to the memory deficits reported in the present study.
However, Kang et al. 16 recently showed that acyl ghrelin rather than des-acyl ghrelin is neuroprotective in AD by activating AMPK, which is a result consistent with the neuroprotective actions of acyl ghrelin, and not des-acyl ghrelin, via AMPK signalling in a mouse model of PD. 26, 64, 65 The activation of AMPK may drive downstream intracellular mitochondrial pathways to prevent degeneration in AD. Indeed, acyl ghrelin treatment reduces reactive oxygen species production and prevents mitochondrial membrane depolarisation in hippocampal and hypothalamic cells treated with Aβ oligomers. 17, 38 These results are similar to the reported actions of acyl ghrelin in the hypothalamus and substantia nigra, as well as in stroke models. 25, 66, 67 suggesting that there are common neuroprotective actions of acyl ghrelin involving the maintenance of mitochondrial homeostasis regardless of the neurological disease.
In conclusion, we have shown that ghrelin deletion impairs spatial and recognition memory, as well as olfactory discrimination. Treatment with Aβ 1-40 i.c.v. significantly impairs spatial and recognition memory in ghrelin WT mice but does not further exacerbate the memory deficit in ghrelin KO mice, suggesting that the loss of endogenous ghrelin signalling may be associated with Aβ 1-40 -induced memory deficits.
Furthermore, the ability of daily i.p. injections of acyl ghrelin to restore spatial and recognition memory performance, as well as hippocampal synaptic plasticity, indicates that enhancing ghrelin secretion may preserve cognitive ability and delay the onset of AD. This supports the idea that acyl ghrelin treatment may be therapeutically beneficial with respect to restricting disease progression in early AD.
